Evidence map›Paper›PMID 32633471›Full record

ArticleCancer medicine2020

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.

Ka-Won Kang, Byung-Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Yong Park, Byung Soo Kim

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Ka-Won KangDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.ORCID 0000-0003-1462-0502
Byung-Hyun LeeDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.ORCID 0000-0003-0603-7923
Min Ji JeonDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Eun Sang YuDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Dae Sik KimDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Se Ryeon LeeDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Hwa Jung SungDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Chul Won ChoiDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Yong ParkDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Byung Soo KimDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Korea University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our aim was to compare the efficacy and safety of two recently developed biosimilars of pegfilgrastim, a pegylated form of the recombinant human granulocyte-colony stimulating factor (G-CSF) analog filgrastim with those of the reference pegfilgrastim. We retrospectively analyzed data from patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who were treated with first-line R-CHOP chemotherapy and received pegylated G-CSF for primary prophylaxis. The following pegylated G-CSFs were analyzed in this study: reference pegfilgrastim (Neulasta

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBacterial InfectionsBiosimilar PharmaceuticalsCyclophosphamideDoxorubicinFebrile NeutropeniaFemaleFilgrastimGranulocyte Colony-Stimulating FactorHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedBiosimilar PharmaceuticalsCyclophosphamideDoxorubicinFilgrastimGranulocyte Colony-Stimulating FactorpegfilgrastimPolyethylene GlycolsPrednisoneR-CHOP protocolRituximabVincristinebiosimilarfebrile neutropenianeutropeniapegylated granulocyte-colony stimulating agent

Identifiers

PMID32633471
PMCPMC7476830
OpenAlexW3040830469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.